GlassScriptPhysician profile
Kaitlin E Leiva
NPI 1336746536
$5,513.20
in general payments reported to CMS, 2019-2025
41 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $591 · 2022: $699 · 2023: $1,343 · 2024: $984 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.81 | 2021-2025 | |
| Boston Scientific Corporation | $764.34 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Foundation Fusion Solutions, LLC | $433.53 | 2025 | |
| Scilex Pharmaceuticals INC. | $401.31 | 2023-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.09 | 2021-2025 | Relistor, Xifaxan |
| Janssen Scientific Affairs, LLC | $361.91 | 2021-2022 | |
| Pfizer INC. | $301.82 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $177.80 | 2023-2025 | Horizant, Horizant |
| Idorsia Pharmaceuticals US INC | $172.16 | 2023-2025 | Quviviq, Quviviq |
| Collegium Pharmaceutical, INC. | $155.71 | 2023-2025 | Xtampza |
| Saluda Medical Americas, INC. | $137.34 | 2024-2025 | Evoke |
| Indivior INC. | $120.19 | 2025 | Sublocade |
| Medtronic, INC. | $116.78 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Almatica Pharma LLC | $106.74 | 2023 | Gralise |
| Gilead Sciences, INC. | $95.63 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $86.25 | 2024 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $78.63 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $66.53 | 2023-2024 | Ajovy |
| Vivus LLC | $55.60 | 2021-2022 | |
| Spr Therapeutics, INC | $44.58 | 2024-2025 | Sprint Pns System |
| Ibsa Pharma INC. | $44.56 | 2023 | Tirosint, Licart |
| Globus Medical, INC. | $41.09 | 2025 | Senza |
| Curonix LLC | $39.91 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Takeda Pharmaceuticals U.S.A., INC. | $37.65 | 2021-2022 | |
| Celgene Corporation | $33.45 | 2021-2022 | |
| Lilly USA, LLC | $32.46 | 2023 | Emgality, Reyvow |
| Qol Medical, LLC | $30.23 | 2021 | |
| Nevro Corp. | $23.06 | 2023 | Senza |
| Si-Bone, INC. | $22.91 | 2024 | |
| Abbott Laboratories | $22.55 | 2023 | Proclaim |
| Nestle Healthcare Nutrition INC. | $22.52 | 2021 | |
| Averitas Pharma INC. | $20.87 | 2025 | Qutenza |
| Avanos Medical | $18.85 | 2024 | Standard Rf Disposables |
| Nalu Medical, INC. | $17.78 | 2025 | Nalu Neurostimulation System |
| Redhill Biopharma INC. | $17.71 | 2022 | |
| Valinor Pharma, LLC | $16.84 | 2025 | Movantik |
| Janssen Biotech, INC. | $16.53 | 2021 | |
| Fidia Pharma USA INC. | $14.16 | 2024 | Triluron, Hyalgan, Hymovis |
| Merck Sharp & Dohme LLC | $14.08 | 2023 | Belsomra |
| Amgen INC. | $13.49 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Leiva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.